Epstein-Barr virus-related mucocutaneous ulcer lymphoma is a rare entity promoted by immunosuppression. It is less described in inflammatory bowel diseases, and mostly these are refractory diseases. CD30 acts to Epstein-Barr virus (EBV) local proliferation and thus could be an interesting target. Brentuximab vedotin could become a new helpful tool.
Keywords: CD30; brentuximab vedotin; epstein‐barr virus; immunosuppression; lymphoma.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.